News

Poniard Pharmaceuticals (Poniard) has announced that 320 evaluable events (patient deaths) have occurred in its pivotal phase 3 SPEAR trial. The trial is being conducted in accordance with

Jim Manzi, chairman of the board, said, “Marc’s strong leadership at Thermo Fisher over the past eight years and his achievements both here and in other companies make

The FDA has approved the design of a single, pivotal, phase III clinical trial evaluating BioVex’s lead product, OncoVEX (GM-CSF), for the first-line treatment of patients with squamous

Cell Therapeutics (CTI) has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for

Amgen has announced that the Court of Appeals for the Federal Circuit affirmed the Massachusetts District Court’s decision that Roche’s peg-EPO product, Mircera, infringes four Amgen patents (‘868,

Lexicon Pharmaceuticals (Lexicon) has initiated a phase 2 clinical trial of the drug candidate in patients with type 2 diabetes mellitus. LX4211 is an orally-delivered, small molecule drug

BioCryst has signed binding letters of intent with three partners who will exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities, as well as for marketing

GENova Biotherapeutics (GENova) has gained access to distribution channels for its drug targets through a recently-signed deal with Bridge BioResearch. Through a recent collaboration deal, the two companies

Pieris has entered into a collaboration agreement with Allergan that combines Pieris’ proprietary Anticalin technology with Allergan’s expertise in drug delivery and ophthalmic drug development with a goal